A modified Park's stitch to correct aortic insufficiency for bioprosthetic valve at time of left ventricular assist device implant: a case report
- 517 Downloads
Aortic valve insufficiency (AI) at the time of left ventricular assist device (LVAD) insertion needs to be corrected, however there is little known about how to manage bioprosthetic valvular AI.
A 55-year-old female with dilated cardiomyopathy who previously had a bioprosthetic aortic valve replacement needed a LVAD as a bridge to transplant. Her left ventricular ejection fraction was 10% and had mild to moderate transvalvular AI. She underwent a HeartWare HVAD insertion along with aortic valvular coaptation stitch repair (Park's stitch) to the bioprosthetic valve.
Her AI improved to trivial with minimal ejection through the bioprosthetic valve. She was transplanted 6 months following the surgery. A Park's stitch to the bioprosthetic aortic valve with more than mild AI might be a good option for bridge to transplant patient.
KeywordsAortic insufficiency Aortic valve repair Park’s stitch Bioprosthetic valve Left ventricular assist device
Continuous flow left ventricular assist devices (LVADs) are known to cause progressive aortic valve commissural fusion as well as progressive aortic insufficiency with greater pump speeds and larger aortic root dimensions [1, 2]. Currently, consensus is to intervene on the aortic valve at the time of LVAD implant if the patient has more than mild aortic insufficiency (AI) (Class I, Level of Evidence C) . The aortic valve can either be repaired or replaced with a bioprosthetic valve. The central coaptation repair stitch (Park’s stitch) has been shown to effectively and durably reduce the AI as well as improve survival, while maintaining aortic valve opening to allow ejection, without the additional cardiopulmonary bypass time that would be required for bioprosthetic valve replacement [4, 5]. This technique has typically been applied to native aortic valves in patients who present with significant AI at the time of LVAD implantation, but there is little known about the application of this technique to patients who present with bioprosthetic transvalvular aortic valve insufficiency at time of LVAD implant. This report demonstrates first clinical application of a Park’s stitch to a patient with a previous bioprosthetic aortic valve replacement (AVR) developing transvalvular AI.
A 55 year-old female with non-ischemic cardiomyopathy who initially presented with multiple syncopal episodes and increasing shortness of breath on exertion for the preceding 2 months. Her left ventricular ejection fraction (LVEF) was 20% at that time, with severe aortic stenosis and mild AI. Her aortic valve area was 1.0 cm2, with a peak gradient 16.9 mmHg and mean gradient 9.2 mmHg gradient. She underwent AVR with a 21 mm Mitroflow (Sorin, Milan, Italy) bioprosthetic valve with significant improvement in her symptoms (aortic valve area 1.8cm2, peak gradient 18.2 mmHg and mean gradient 9.0 mmHg).
Little has been known about management of recurrent AI after bioprosthetic AVR at the time of LVAD placement. A central coaptation stitch to these patients potentially is a good option for a bridge to transplant.
Short-term follow up in this patient shows promising results with only trace AI on echocardiogram. Although this technique has been shown to be a durable solution for patients with significant native aortic valve insufficiency , the long-term results of this technique especially in bioprosthetic valves remains to be seen to determine the durability of these results in the face of continued bioprosthetic valve degeneration.
Although there have been numerous studies of AI in LVAD patients, we don't know the long-term prognosis of patients who develops acquired AI. Since AI seemed to have negative impact on survival [1, 6], either bioprosthetic AVR or aortic valve repair is recommended for these patients. Patients with AI with following a previous bioprosthetic AVR, no recommendation is currently available. Performing a re-replacement bioprosthetic AVR may be more durable to prevent leaflet fusion, however explanting a previous valve and re-implant new valve in patients having an LVAD placement with concomitant severe RV dysfunction raises concerns about further impairing postoperative RV function. A Park's stitch to a bioprosthetic AVR is relatively easy, timely, safe and durable in LVAD patients being bridged to transplant.
This procedure was able to be performed in a quick and effective manner with short aortic cross clamp time to minimize the risk of RV dysfunction after LVAD placement.
The limitation of this technique in the setting of previous bioprosthetic AVR is no long-term mortality and morbidity data reported, therefore the application of this technique to destination patients should be cautious because of aortic valve leaflet fusion and potential thrombus formation below the fused aortic valve. If patients with AI from degenerating bioprosthetic AVR is listed as bridge to transplant, a Park's stitch to the bioprosthetic valve leaflets might be a good option to consider.
In conclusion, we reported a first successful case with Park's stitch and LVAD placement to previously placed bioprosthetic AVR. Further studies are mandatory to prove longevity and survival of this procedure in this context.
We would like to thank Destiny Dicken for her contribution on the submission process.
There was no funding for this case report.
Availability of data and materials
The data supporting the results is available.
The individual contributions of authors to the manuscript should be specified in this section. TK: Performed the surgery, writing the manuscript, data collecting. NS: writing manuscript, data collecting. MF: patient management, correct the manuscript. SK: correct the manuscript. SL: performed the surgery, correct the manuscript. ZK: performed the surgery, correct the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
The consent for publication was obtained.
Ethics approval and consent to participate
Manuscripts reporting studies involving human participants, human data or human tissue must: Include a statement on ethics approval and consent (even where the need for approval was waived). Per institutional protocol, ethics approval and consent was waived.
- 3.Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohacsi P, Mooney M, Nelson T, Pagani F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J, International Society for Heart and Lung Transplantation. The 2013 international society for heart and lung transplantation guidelines for mechanical circulatory support: Executive summary. J Heart Lung Transplant. 2013;32:157–87.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.